Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRE-EMPT: Precision Phenotyping of Behavioral Risk and Response to Electromagnetic and Psychedelic Therapies
NCT07745569Phase 2Not yet recruiting
- Sponsor
- The University of New Mexico
- Start
- Dec 2026
- Primary completion
- Jun 2030
01
Overview
Phase 2, randomised, single-blind trial of psilocybin in major depressive disorder (MDD), post-traumatic stress disorder (PTSD) and Suicidality (3 arms), sponsored by The University of New Mexico. Primary endpoint: Neurofeedback. Planned start Dec 2026; status: not yet recruiting.
02
Drugs
psilocybin
03
Conditions
major depressive disorder (MDD)post-traumatic stress disorder (PTSD)Suicidality
Beyond the preview
Go deeper on NCT07745569.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07745569.